Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1382-1387

  Kim, S J ^a   Kim, B S ^a,b   Choi, C W ^a   Choi, J ^a   Kim, I ^a   Lee, Y H ^a   Kim, J S ^a  

^a Korea University Ansan Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Extranodal lymphoma; Ki 67; NK T cell; Prognosis

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; KI 67 ANTIGEN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NOSE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA;

EID: 34548158504     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm183     Document Type: Article

References (25)

1. Jaffe ES, Chan JK, Su IJ et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.
2. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia November 1997. J Clin Oncol 1999; 17: 3835-3849.
3. Aozasa K, Ohsawa M, Tajima K et al. Nation-wide study of lethal mid-line granuloma in Japan: Frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 1989; 44: 63-66.
4. Ko YH, Kim CW, Park CS et al. REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 806-812.
5. Kanavaros P, Lescs MC, Briere J et al. Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688-2695.
6. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
7. Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/ II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785-3790.
8. Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54-63.
9. Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of theraphy. Eur J Cancer 2005; 41: 1402-1408.
10. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
11. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
12. Aviles A, Diaz NR, Neri N et al. Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22: 215-220.
13. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-prognostic score. J Clin Oncol 2006; 24: 2472-2479.
14. Kim SJ, Kim BS, Choi CW et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leukemia Lymphoma 2006; 47: 1265-1273.
15. Saez A, Sanchez E, Sanchez-Beato M et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 1999; 80: 1427-1434.
16. Fillpits M, Jaeger U, Pohl G et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8: 729-733.
17. Lapela M, Leskinen S, Minn HR et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
18. Patruno R, Zizzo N, Zito AF et al. Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model. Leukemia Lymphoma 2006; 47: 1138-1143.
19. Schluter C, Duchrow M, Wohlenberg C et al. The cell proliferation-associated antigen of antibody Ki-67: A very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123: 513-522.
20. Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
21. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000; 182: 311-322.
22. Grogan TM, Lippman SM, Spier CM et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157-1160.
23. Hall PA, Richards MA, Gregory WM et al. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 154: 223-235.
24. Jerkeman M, Anderson H, Dictor M et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol 2004; 83: 414-419.
25. Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-1466.